LHM Inc. trimmed its position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 29.9% during the 4th quarter, HoldingsChannel reports. The fund owned 83,738 shares of the exchange traded fund’s stock after selling 35,802 shares during the quarter. SPDR S&P Biotech ETF makes up approximately 3.8% of LHM Inc.’s investment portfolio, making the stock its 5th biggest holding. LHM Inc.’s holdings in SPDR S&P Biotech ETF were worth $10,210,000 as of its most recent SEC filing.
Other hedge funds also recently modified their holdings of the company. JPMorgan Chase & Co. increased its position in shares of SPDR S&P Biotech ETF by 27.3% during the third quarter. JPMorgan Chase & Co. now owns 13,538,738 shares of the exchange traded fund’s stock valued at $1,356,582,000 after purchasing an additional 2,900,633 shares during the period. Bessemer Group Inc. increased its holdings in SPDR S&P Biotech ETF by 13.5% in the 4th quarter. Bessemer Group Inc. now owns 1,853,232 shares of the exchange traded fund’s stock valued at $225,965,000 after buying an additional 220,244 shares during the period. Ameriprise Financial Inc. raised its stake in shares of SPDR S&P Biotech ETF by 40.5% in the 3rd quarter. Ameriprise Financial Inc. now owns 1,226,147 shares of the exchange traded fund’s stock valued at $122,906,000 after buying an additional 353,351 shares in the last quarter. Greenhouse Funds LLLP lifted its holdings in shares of SPDR S&P Biotech ETF by 16.6% during the 3rd quarter. Greenhouse Funds LLLP now owns 675,975 shares of the exchange traded fund’s stock worth $67,733,000 after acquiring an additional 96,308 shares during the period. Finally, Assetmark Inc. boosted its position in shares of SPDR S&P Biotech ETF by 1,042,265.6% during the 4th quarter. Assetmark Inc. now owns 635,843 shares of the exchange traded fund’s stock valued at $77,528,000 after acquiring an additional 635,782 shares in the last quarter.
SPDR S&P Biotech ETF Stock Up 1.1%
NYSEARCA XBI opened at $135.99 on Friday. The stock has a market cap of $8.68 billion, a P/E ratio of 11.47 and a beta of 0.85. The company’s 50-day simple moving average is $130.68 and its 200 day simple moving average is $125.86. SPDR S&P Biotech ETF has a twelve month low of $78.06 and a twelve month high of $139.19.
About SPDR S&P Biotech ETF
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
See Also
- Five stocks we like better than SPDR S&P Biotech ETF
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
- Snowflake and the Snowballing Impact of its AI Flywheel
- AI’s Biggest Bottleneck Could Make These 2 Stocks Soar
- These 3 Beaten-Down Stocks Just Saw $25 Million in Insider Buying
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
